Diagnostic utility of transabdominal ultrasound combined with Doppler in ovarian tumors
Abstract
Introduction: Ovarian tumors constitute a health problem in women, with a silent progression that hinders early diagnosis and shows a growing trend. Transabdominal ultrasound with Doppler provides information on the malignant potential of adnexal masses.
Objective: To determine the diagnostic utility of transabdominal ultrasound with Doppler in adnexal tumor lesions at the Manuel Fajardo Clinical-Surgical Hospital.
Method: A prospective longitudinal descriptive study was conducted in 47 patients with a positive finding of adnexal tumor by transabdominal ultrasound with Doppler, from 2019 to 2022.
Results: Patients at high risk for ovarian cancer through ultrasound had a mean age of 55,6 years (±12,2), higher than that of patients without risk (55,6 years, ±10.9; p=0.00). The main findings were central Doppler vascularization and a resistance index less than 0,5, both present in 70,2 % of cases. The most frequent benign histological type was serous cystadenoma (12,8 %), while among malignant types, cystadenocarcinoma predominated (59,6 %). A sensitivity of 94,1 %, specificity of 92,3 %, and positive and negative predictive values of 97,0 % and 85,6 %, respectively, were obtained.
Conclusions: Most of the findings linked to cancer risk were observed using Doppler ultrasound. From an histological point of view, malignant tumors were the most frequent diagnoses. Together, transabdominal ultrasound and Doppler constitute valuable tools to more accurately predict the benign or malignant nature of adnexal tumors.
Downloads
References
1. Centro Internacional de Investigaciones sobre el Cáncer. Crece la carga mundial de cáncer en medio de una creciente necesidad de servicios. Ginebra: Organización Mundial de la Salud. 2024 [citado 01/01/2026]. Disponible en: https://www.who.int/es/news/item/01-02-2024-global-cancer-burdengrowing--amidst-mounting-need-for-services
2. National Cancer Institutr. Estados Unidos de Norteamérica: Estados Unidos de Norteamérica. 2025 [citado 01/01/2026]. Cancer Statistics; [aprox. 5 p]. Disponible en: https://www.cancer.gov/about-cancer/understanding/statistics
3. Organización Panamericana de la Salud. Oficina Regional para las Américas de la Organización Mundial de la Salud, Washington, D.C, Estados Unidos de Norteamérica: OPS/OMS. c2025 [citado 01/01/2026]. Cáncer; [aprox. 2 p]. Disponible en: https://www.paho.org/es/temas/cancer
4. Filho AM, Laversanne M, Ferlay J, Colombet M, Piñeros M, Znaor A et al. The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide. Int J Cancer. 2025 [citado 01/01/2026];156(7):1336-46. Disponible en: https://doi.org/10.1002/ijc.35278
5. Cuba. Ministerio de Salud Pública. Dirección de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud 2024. La Habana: MINSAP. 2025 [citado 14/01/2026]. Disponible en: https://files.sld.cu/dne/files/2025/09/AES-2024-para-sitio-3.pdf
6. Pertejo-Fernández A, Pedregosa-Barbas J, Castelo-Fernández B, Redondo-Sánchez A. Epidemiología e historia natural del cáncer de ovario. Rev Cáncer. 2024[citado 14/01/2026];38(4):149-55. Disponible en: https://doi.org/10.20960/revcancer.00087
7. Rocha-Monjarás B. Ácido siálico y otros factores asociados en el diagnóstico de cáncer de ovario en pacientes con masas anexiales [Tesis]. San Luis Potosí: Universidad Autónoma de San Luis Potosí. 2020 [citado 11/01/2026]: 50. Disponible en: https://repositorioinstitucional.uaslp.mx/xmlui/bitstream/handle/i/5928/TesisE.FM.2020.%c3%81cido.Rocha.pdf?sequence=3&isAllowed=y
8. Martín Martínez A, Medina Ramos N, Coterón Obregón J, Zubiría Pineda A., García Hernández J.A. Estudio doppler en tumoraciones anexiales sospechas de malignidad. Canarias Médica y Quirúrgica. 2003 [citado 20/11/2025]; 1(1):35-9. Disponible en: https://accedacris.ulpgc.es/bitstream/10553/6502/1/0514198_00001_0008.pdf
9.Kudla MJ, Zikan M, Fischerova D, Stolecki M, Alcazar JL. 4D Doppler Ultrasound in High Grade Serous Ovarian Cancer Vascularity Evaluation-Preliminary Study. Diagnostics (Basel). 2021 [citado 24/31/2025];11(4):582. Disponible en: https://doi.org/10.3390/diagnostics11040582
10.Wheeler V, Umstead B, Chadwick C. Adnexal masses: diagnosis and management. Am Fam Physician. 2023 [citado 11/012026];108(6):580-7. Disponible en: https://www.aafp.org/pubs/afp/issues/2023/1200/adnexal-masses.html
11. World Health Organization. Female genital tumours. Lyon: IARC Press; 2020. (WHO classification of tumours series, 5th ed.; vol. 4). Chapter 1, Tumours of the ovary; 31-163p.
12. González Fernández H, Morales-Yera RA, Santana-Rodríguez SM, Reinoso Padrón L, Heredia Martínez BE. Caracterización clínico-epidemiológica del cáncer de ovario. Rev Finlay. 2021 [citado 11/12/2025];11(4):359-70. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S2221-24342021000400359&lng=es
13. Pertejo Fernández A, Pedregosa Barbas J, Castelo B. Epidemiología e historia natural del cáncer de ovario. revisiones en Cáncer. Hospital Universitario La Paz. Madrid. 2024 [citado 25/12/2025]:23. Disponible en: https://pmc-ncbi-nlm-nihgov.translate.goog/articles/PMC5365187/?_x_tr_sl=en&_x_tr_tl=es&_x_tr_hl=es&_x_tr_pto=tc
14. Chávarri-Guerra Y, González-Ochoa E, De la Mora Molina H, Soto-Pérez de Celis, E. Systemic therapy for non-serous ovarian carcinoma. Chinese clinical oncology.2020[citado 25/12/2025];9(4):52. Disponible en: https://cco.amegroups.org/article/view/48096/html
15. Matías Martínez M. Evaluación de un protocolo de actuación frente a masas anexiales basado en la clasificación GI-RADS, el marcador tumoral HE4 y el estado hormonal [Tesis]. Madrid: Universidad Rey Juan Carlos. 2020 [citado 23/10/2025]. Disponible en: https://dialnet.unirioja.es/servlet/tesis?codigo=300881
16. Otero-Leyva M, Almeida-Esquivel Y, Piñón-García K, Creagh-García J, Ramos-García DE. Caracterización clínica e histopatológica de pacientes con cáncer de ovario. Rev Cienc Méd. 2023 [citado 13/01/2026];27(5):e5974. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S156131942023000600022&lng=es
17. Álvarez Sánchez AC. Correlación ultrasonográfica e histopatológica de los tumores de ovario. Rev cubana Obstet Ginecol. 2010 [citado 10/12/2025]; 36 (1):86-96. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0138600X2010000100011&lng=es
18. Basha MAA, Metwally MI, Gamil SA, Khater HM, Aly SA, El Sammak AA, et al. Comparison of O-RADS, GI-RADS, and IOTA simple rules regarding malignancy rate, validity, and reliability for diagnosis of adnexal masses. Eur Radiol. 2021[citado 10/12/2025];31(2):674-84. Disponible en: https://www.researchgate.net/publication/343723865_Comparison_of_O-RADS_GI-RADS_and_IOTA_simple_rules_regarding_malignancy_rate_validity_and_reliability_for_diagnosis_of_adnexal_masses
19. del Campo JM. Cáncer de ovario. Sociedad Española de Oncología Médica. SEOM. © 2026[citado 10/02/2026]. Disponible en: https://seom.org/info-sobre-el-cancer/ovario?showall=1&showall=1
20. Tavoraitė I, Kronlachner L, Opolskienė G, Bartkevičienė D. Ultrasound Assessment of Adnexal Pathology: Standardized Methods and Different Levels of Experience. Medicina (Kaunas). 2021[citado 10/12/2025];57(7):708. Disponible en: https://www.researchgate.net/publication/353756034_Ultrasound_Assessment_of_Adnexal_Pathology_Standardized_Methods_and_Different_Levels_of_Experience
21. El-Salam SA, Hamed ST, El-Ghafar SMA. Diagnostic performance of GI-RADS reporting system in evaluation of adnexal masses. Egypt J Radiol Nucl Med. 2020[citado 10/12/2025];51(1):60. Disponible en. https://www.researchgate.net/publication/340790891_Diagnostic_performance_of_GI-RADS_reporting_system_in_evaluation_of_adnexal_masses
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Ana Maris Alfonso Albarrán, Ana Maris Alfonso Albarrán

This work is licensed under a Creative Commons Attribution 4.0 International License.
All the articles can be downloaded or read for free. The journal does not charge any amount of money to the authors for the reception, edition or the publication of the articles, making the whole process completely free. Medisan has no embargo period and it is published under the license of Creative Commons, International Non Commercial Recognition 4.0, which authorizes the copy, reproduction and the total or partial distribution of the articles in any format or platform, with the conditions of citing the source of information and not to be used for profitable purposes.
